{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:29:09Z","timestamp":1770812949700,"version":"3.50.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81730078"],"award-info":[{"award-number":["81730078"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>TSC2, a suppressor of mTOR, is inactivated in up to 20% of HBV-associated liver cancer. This subtype of liver cancer is associated with aggressive behavior and early recurrence after hepatectomy. Being the first targeted regimen for advanced liver cancer, sorafenib has limited efficacy in HBV-positive patients. In this study, we observed that mTOR-activated cells, due to the loss of either TSC2 or PTEN, were insensitive to the treatment of sorafenib. Mechanistically, HSP70 enhanced the interaction between active mTOR-potentiated CREB1 and CREBBP to boost the transcription of the antioxidant response regulator SESN3. In return, elevated SESN3 enhanced cellular antioxidant capacity and rendered cells resistant to sorafenib. Pifithrin-\u03bc, an HSP70 inhibitor, synergized with sorafenib in the induction of ferroptosis in mTOR-activated liver cancer cells and suppression of TSC2-deficient hepatocarcinogenesis. Our findings highlight the pivotal role of the mTOR-CREB1-SESN3 axis in sorafenib resistance of liver cancer and pave the way for combining pifithrin-\u03bc and sorafenib for the treatment of mTOR-activated liver cancer.<\/jats:p>","DOI":"10.1038\/s41419-025-07332-6","type":"journal-article","created":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:36:36Z","timestamp":1737851796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pifithrin-\u03bc sensitizes mTOR-activated liver cancer to sorafenib treatment"],"prefix":"10.1038","volume":"16","author":[{"given":"Jiarui","family":"Lv","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiacheng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuiting","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linyan","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6291-1027","authenticated-orcid":false,"given":"Hongbing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,26]]},"reference":[{"key":"7332_CR1","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","volume":"20","author":"AG Singal","year":"2023","unstructured":"Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023;20:864\u201384.","journal-title":"Nat Rev Clin Oncol"},{"key":"7332_CR2","doi-asserted-by":"crossref","unstructured":"Tan EY, Danpanichkul P, Yong JN, Yu Z, Tan DJH, Lim WH, et al. Liver cancer in 2021: global burden of disease study. J Hepatol. 2024;S0168-8278:02652-7.","DOI":"10.1016\/j.jhep.2024.10.031"},{"key":"7332_CR3","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77:1598\u2013606.","journal-title":"J Hepatol"},{"key":"7332_CR4","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/j.jhep.2022.12.002","volume":"78","author":"C Li","year":"2023","unstructured":"Li C, He WQ. Global prediction of primary liver cancer incidences and mortality in 2040. J Hepatol. 2023;78:e144\u2013e146.","journal-title":"J Hepatol"},{"key":"7332_CR5","doi-asserted-by":"publisher","first-page":"554","DOI":"10.21147\/j.issn.1000-9604.2022.06.02","volume":"34","author":"Q Li","year":"2022","unstructured":"Li Q, Cao M, Lei L, Yang F, Li H, Yan X, et al. Burden of liver cancer: from epidemiology to prevention. Chin J Cancer Res. 2022;34:554\u201366.","journal-title":"Chin J Cancer Res"},{"key":"7332_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4:47\u201353.","journal-title":"J Natl Cancer Cent"},{"key":"7332_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","volume":"161","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Ferlay J, de Martel C, Georges D, Ibrahim AS, Zheng R, et al. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer. 2022;161:108\u201318.","journal-title":"Eur J Cancer"},{"key":"7332_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","volume":"20","author":"C Yang","year":"2023","unstructured":"Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2023;20:203\u201322.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"7332_CR9","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.3390\/cancers16081582","volume":"16","author":"S Zheng","year":"2024","unstructured":"Zheng S, Chan SW, Liu F, Liu J, Chow PKH, Toh HC, et al. Hepatocellular carcinoma: current drug therapeutic status, advances and challenges. Cancers (Basel). 2024;16:1582.","journal-title":"Cancers (Basel)"},{"key":"7332_CR10","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1200\/JCO.2016.69.5197","volume":"35","author":"R Jackson","year":"2017","unstructured":"Jackson R, Psarelli EE, Berhane S, Khan H, Johnson P. Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer: a meta-analysis of randomized phase III trials. J Clin Oncol. 2017;35:622\u20138.","journal-title":"J Clin Oncol"},{"key":"7332_CR11","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","volume":"5","author":"A Huang","year":"2020","unstructured":"Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5:146.","journal-title":"Signal Transduct Target Ther"},{"key":"7332_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","volume":"5","author":"W Tang","year":"2020","unstructured":"Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5:87.","journal-title":"Signal Transduct Target Ther"},{"key":"7332_CR13","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2147\/JHC.S285726","volume":"8","author":"F Fornari","year":"2021","unstructured":"Fornari F, Giovannini C, Piscaglia F, Gramantieri L. Elucidating the molecular basis of sorafenib resistance in HCC: current findings and future directions. J Hepatocell Carcinoma. 2021;8:741\u201357.","journal-title":"J Hepatocell Carcinoma"},{"key":"7332_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102644","volume":"52","author":"J Chen","year":"2020","unstructured":"Chen J, Duda DG. Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: a future perspective at a time of rapidly changing treatment paradigms. EBioMedicine. 2020;52:102644.","journal-title":"EBioMedicine"},{"key":"7332_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.102610","volume":"51","author":"S Xia","year":"2020","unstructured":"Xia S, Pan Y, Liang Y, Xu J, Cai X. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine. 2020;51:102610.","journal-title":"EBioMedicine"},{"key":"7332_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0159-1","volume":"50","author":"C Mendez-Blanco","year":"2018","unstructured":"Mendez-Blanco C, Fondevila F, Garcia-Palomo A, Gonzalez-Gallego J, Mauriz JL. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors. Exp Mol Med. 2018;50:1\u20139.","journal-title":"Exp Mol Med"},{"key":"7332_CR17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41392-021-00594-4","volume":"6","author":"J Xu","year":"2021","unstructured":"Xu J, Ji L, Ruan Y, Wan Z, Lin Z, Xia S, et al. UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1beta in hepatocellular carcinoma. Signal Transduct Target Ther. 2021;6:190.","journal-title":"Signal Transduct Target Ther"},{"key":"7332_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1207496","volume":"14","author":"L Guo","year":"2023","unstructured":"Guo L, Hu C, Yao M, Han G. Mechanism of sorafenib resistance associated with ferroptosis in HCC. Front Pharm. 2023;14:1207496.","journal-title":"Front Pharm"},{"key":"7332_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175913","volume":"955","author":"Q Li","year":"2023","unstructured":"Li Q, Chen K, Zhang T, Jiang D, Chen L, Jiang J, et al. Understanding sorafenib-induced ferroptosis and resistance mechanisms: Implications for cancer therapy. Eur J Pharm. 2023;955:175913.","journal-title":"Eur J Pharm"},{"key":"7332_CR20","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/hmg\/11.5.525","volume":"11","author":"DJ Kwiatkowski","year":"2002","unstructured":"Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, el-Hashemite N, et al. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet. 2002;11:525\u201334.","journal-title":"Hum Mol Genet"},{"key":"7332_CR21","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/ncb839","volume":"4","author":"K Inoki","year":"2002","unstructured":"Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4:648\u201357.","journal-title":"Nat Cell Biol"},{"key":"7332_CR22","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/ncb840","volume":"4","author":"CJ Potter","year":"2002","unstructured":"Potter CJ, Pedraza LG, Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol. 2002;4:658\u201365.","journal-title":"Nat Cell Biol"},{"key":"7332_CR23","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/ncb847","volume":"4","author":"X Gao","year":"2002","unstructured":"Gao X, Zhang Y, Arrazola P, Hino O, Kobayashi T, Yeung RS, et al. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol. 2002;4:699\u2013704.","journal-title":"Nat Cell Biol"},{"key":"7332_CR24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S1097-2765(02)00568-3","volume":"10","author":"BD Manning","year":"2002","unstructured":"Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase\/akt pathway. Mol Cell. 2002;10:151\u201362.","journal-title":"Mol Cell"},{"key":"7332_CR25","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41568-018-0074-8","volume":"18","author":"D Mossmann","year":"2018","unstructured":"Mossmann D, Park S, Hall MN. mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer. 2018;18:744\u201357.","journal-title":"Nat Rev Cancer"},{"key":"7332_CR26","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/hep.26323","volume":"58","author":"M Bhat","year":"2013","unstructured":"Bhat M, Sonenberg N, Gores GJ. The mTOR pathway in hepatic malignancies. Hepatology. 2013;58:810\u20138.","journal-title":"Hepatology"},{"key":"7332_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12032-009-9201-4","volume":"27","author":"L Zhou","year":"2010","unstructured":"Zhou L, Huang Y, Li J, Wang Z. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol. 2010;27:255\u201361.","journal-title":"Med Oncol"},{"key":"7332_CR28","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.jhep.2013.11.031","volume":"60","author":"MS Matter","year":"2014","unstructured":"Matter MS, Decaens T, Andersen JB, Thorgeirsson SS. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol. 2014;60:855\u201365.","journal-title":"J Hepatol"},{"key":"7332_CR29","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1002\/cncr.11266","volume":"97","author":"TH Hu","year":"2003","unstructured":"Hu TH, Huang CC, Lin PR, Chang HW, Ger LP, Lin YW, et al. Expression and prognostic role of tumor suppressor gene PTEN\/MMAC1\/TEP1 in hepatocellular carcinoma. Cancer. 2003;97:1929\u201340.","journal-title":"Cancer"},{"key":"7332_CR30","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1136\/gutjnl-2016-312734","volume":"66","author":"DWH Ho","year":"2017","unstructured":"Ho DWH, Chan LK, Chiu YT, Xu IMJ, Poon RTP, Cheung TT, et al. TSC1\/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication. Gut. 2017;66:1496\u2013506.","journal-title":"Gut"},{"key":"7332_CR31","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1158\/1535-7163.MCT-14-0768","volume":"14","author":"H Huynh","year":"2015","unstructured":"Huynh H, Hao HX, Chan SL, Chen D, Ong R, Soo KC, et al. Loss of tuberous sclerosis complex 2 (TSC2) is frequent in hepatocellular carcinoma and predicts response to mTORC1 inhibitor everolimus. Mol Cancer Ther. 2015;14:1224\u201335.","journal-title":"Mol Cancer Ther"},{"key":"7332_CR32","first-page":"269","volume":"14","author":"K Song","year":"2021","unstructured":"Song K, He F, Xin Y, Guan G, Huo J, Zhu Q, et al. TSC2 mutations were associated with the early recurrence of patients with HCC underwent hepatectomy. Pharmgenomics Pers Med. 2021;14:269\u201378.","journal-title":"Pharmgenomics Pers Med"},{"key":"7332_CR33","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41586-024-07054-3","volume":"627","author":"L Chen","year":"2024","unstructured":"Chen L, Zhang C, Xue R, Liu M, Bai J, Bao J, et al. Deep whole-genome analysis of 494 hepatocellular carcinomas. Nature. 2024;627:586\u201393.","journal-title":"Nature"},{"key":"7332_CR34","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1074\/mcp.M113.033845","volume":"13","author":"M Masuda","year":"2014","unstructured":"Masuda M, Chen WY, Miyanaga A, Nakamura Y, Kawasaki K, Sakuma T, et al. Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling. Mol Cell Proteom. 2014;13:1429\u201338.","journal-title":"Mol Cell Proteom"},{"key":"7332_CR35","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa063564","volume":"358","author":"JJ Bissler","year":"2008","unstructured":"Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl J Med. 2008;358:140\u201351.","journal-title":"N. Engl J Med"},{"key":"7332_CR36","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","volume":"364","author":"FX McCormack","year":"2011","unstructured":"McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N. Engl J Med. 2011;364:1595\u2013606.","journal-title":"N. Engl J Med"},{"key":"7332_CR37","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1158\/0008-5472.CAN-22-0602","volume":"82","author":"KC Wood","year":"2022","unstructured":"Wood KC, Gutkind JS. Challenges and emerging opportunities for targeting mTOR in cancer. Cancer Res. 2022;82:3884\u20137.","journal-title":"Cancer Res"},{"key":"7332_CR38","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1158\/1078-0432.CCR-20-4548","volume":"27","author":"E Adib","year":"2021","unstructured":"Adib E, Klonowska K, Giannikou K, Do KT, Pruitt-Thompson S, Bhushan K, et al. Phase II clinical trial of everolimus in a pan-cancer cohort of patients with mTOR pathway alterations. Clin Cancer Res. 2021;27:3845\u201353.","journal-title":"Clin Cancer Res"},{"key":"7332_CR39","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3390\/ijms21041266","volume":"21","author":"G Ferrin","year":"2020","unstructured":"Ferrin G, Guerrero M, Amado V, Rodriguez-Peralvarez M, De la Mata M. Activation of mTOR signaling pathway in hepatocellular carcinoma. Int J Mol Sci. 2020;21:1266.","journal-title":"Int J Mol Sci"},{"key":"7332_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/jama.2014.7189","volume":"312","author":"AX Zhu","year":"2014","unstructured":"Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA. 2014;312:57\u201367.","journal-title":"JAMA"},{"key":"7332_CR41","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/annonc\/mdw054","volume":"27","author":"D Koeberle","year":"2016","unstructured":"Koeberle D, Dufour JF, Demeter G, Li Q, Ribi K, Samaras P, et al. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77\/08 and SASL 29). Ann Oncol. 2016;27:856\u201361.","journal-title":"Ann Oncol"},{"key":"7332_CR42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2202157119","volume":"119","author":"F Liu","year":"2022","unstructured":"Liu F, Gai X, Wu Y, Zhang B, Wu X, Cheng R, et al. Oncogenic beta-catenin stimulation of AKT2-CAD-mediated pyrimidine synthesis is targetable vulnerability in liver cancer. Proc Natl Acad Sci USA. 2022;119:e2202157119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7332_CR43","doi-asserted-by":"crossref","unstructured":"Liu F, Wu Y, Zhang B, Yang S, Shang K, Li J, et al. Oncogenic beta-catenin-driven liver cancer is susceptible to methotrexate-mediated disruption of nucleotide synthesis. Chin Med J (Engl) 2023;137:181\u20139.","DOI":"10.1097\/CM9.0000000000002816"},{"key":"7332_CR44","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1038\/s41418-019-0274-0","volume":"26","author":"C Li","year":"2019","unstructured":"Li C, Chen H, Lan Z, He S, Chen R, Wang F, et al. mTOR-dependent upregulation of xCT blocks melanin synthesis and promotes tumorigenesis. Cell Death Differ. 2019;26:2015\u201328.","journal-title":"Cell Death Differ"},{"key":"7332_CR45","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1074\/jbc.274.7.4266","volume":"274","author":"M Vilella-Bach","year":"1999","unstructured":"Vilella-Bach M, Nuzzi P, Fang Y, Chen J. The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression. J Biol Chem. 1999;274:4266\u201372.","journal-title":"J Biol Chem"},{"key":"7332_CR46","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.molcel.2010.06.022","volume":"39","author":"K Duvel","year":"2010","unstructured":"Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell. 2010;39:171\u201383.","journal-title":"Mol Cell"},{"key":"7332_CR47","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021;18:280\u201396.","journal-title":"Nat Rev Clin Oncol"},{"key":"7332_CR48","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ccell.2020.06.001","volume":"38","author":"JD Hayes","year":"2020","unstructured":"Hayes JD, Dinkova-Kostova AT, Tew KD. Oxidative stress in cancer. Cancer Cell. 2020;38:167\u201397.","journal-title":"Cancer Cell"},{"key":"7332_CR49","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.4161\/auto.26447","volume":"9","author":"Y Wang","year":"2013","unstructured":"Wang Y, Hu Z, Liu Z, Chen R, Peng H, Guo J, et al. MTOR inhibition attenuates DNA damage and apoptosis through autophagy-mediated suppression of CREB1. Autophagy. 2013;9:2069\u201386.","journal-title":"Autophagy"},{"key":"7332_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.113311","volume":"292","author":"S Ohayon","year":"2020","unstructured":"Ohayon S, Yitzhaky A, Hertzberg L. Gene expression meta-analysis reveals the up-regulation of CREB1 and CREBBP in Brodmann Area 10 of patients with schizophrenia. Psychiatry Res. 2020;292:113311.","journal-title":"Psychiatry Res"},{"key":"7332_CR51","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/15592294.2016.1265710","volume":"12","author":"M Perez-Salvia","year":"2017","unstructured":"Perez-Salvia M, Esteller M. Bromodomain inhibitors and cancer therapy: from structures to applications. Epigenetics. 2017;12:323\u201339.","journal-title":"Epigenetics"},{"key":"7332_CR52","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41580-019-0133-3","volume":"20","author":"R Rosenzweig","year":"2019","unstructured":"Rosenzweig R, Nillegoda NB, Mayer MP, Bukau B. The Hsp70 chaperone network. Nat Rev Mol Cell Biol. 2019;20:665\u201380.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"7332_CR53","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1053\/j.gastro.2008.08.008","volume":"135","author":"A Villanueva","year":"2008","unstructured":"Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135:1972\u201383.","journal-title":"Gastroenterology"},{"key":"7332_CR54","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1002\/hep.30467","volume":"69","author":"D Lee","year":"2019","unstructured":"Lee D, Xu IM, Chiu DK, Leibold J, Tse AP, Bao MH, et al. Induction of oxidative stress through inhibition of thioredoxin reductase 1 is an effective therapeutic approach for hepatocellular carcinoma. Hepatology. 2019;69:1768\u201386.","journal-title":"Hepatology"},{"key":"7332_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0648-1","volume":"16","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, Hu X, Liu Y, Dong S, Wen Z, He W, et al. ROS signaling under metabolic stress: cross-talk between AMPK and AKT pathway. Mol Cancer. 2017;16:79.","journal-title":"Mol Cancer"},{"key":"7332_CR56","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.1158\/0008-5472.CAN-06-2466","volume":"67","author":"PB Kopnin","year":"2007","unstructured":"Kopnin PB, Agapova LS, Kopnin BP, Chumakov PM. Repression of sestrin family genes contributes to oncogenic Ras-induced reactive oxygen species up-regulation and genetic instability. Cancer Res. 2007;67:4671\u20138.","journal-title":"Cancer Res"},{"key":"7332_CR57","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1007\/s00018-020-03525-8","volume":"77","author":"A Steven","year":"2020","unstructured":"Steven A, Friedrich M, Jank P, Heimer N, Budczies J, Denkert C, et al. What turns CREB on? And off? And why does it matter? Cell Mol Life Sci. 2020;77:4049\u201367.","journal-title":"Cell Mol Life Sci"},{"key":"7332_CR58","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrm2941","volume":"11","author":"HH Kampinga","year":"2010","unstructured":"Kampinga HH, Craig EA. The HSP70 chaperone machinery: J proteins as drivers of functional specificity. Nat Rev Mol Cell Biol. 2010;11:579\u201392.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"7332_CR59","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1053\/jhep.2003.50022","volume":"37","author":"M Chuma","year":"2003","unstructured":"Chuma M, Sakamoto M, Yamazaki K, Ohta T, Ohki M, Asaka M, et al. Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology. 2003;37:198\u2013207.","journal-title":"Hepatology"},{"key":"7332_CR60","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.molcel.2009.09.023","volume":"36","author":"JI Leu","year":"2009","unstructured":"Leu JI, Pimkina J, Frank A, Murphy ME, George DL. A small molecule inhibitor of inducible heat shock protein 70. Mol Cell. 2009;36:15\u201327.","journal-title":"Mol Cell"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07332-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07332-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07332-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T01:29:57Z","timestamp":1737854997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07332-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,26]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7332"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07332-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,26]]},"assertion":[{"value":"3 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All the animal protocols were approved by the Animal Center of the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, and Peking Union Medical College (ACUC-A01-2022-023) and abided by the regulations of the Beijing Administration Office of Laboratory Animal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"42"}}